Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

600 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer.
Pope B, Park G, Lau E, Belic J, Lach R, George A, McCoy P, Nguyen A, Grima C, Campbell B, Jung CH, Ditter EJ, Zhao H; Pan Prostate Cancer Group (PPCG); Wedge DC, Brewer DS, Lynch AG, Dev H, Gnanpragasam VJ, Rosenfeld N, Hovens CM, Corcoran NM, Massie CE. Pope B, et al. Eur Urol. 2024 Apr;85(4):407-410. doi: 10.1016/j.eururo.2024.01.002. Epub 2024 Feb 19. Eur Urol. 2024. PMID: 38378299 No abstract available.
Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression.
Lau E, McCoy P, Reeves F, Chow K, Clarkson M, Kwan EM, Packwood K, Northen H, He M, Kingsbury Z, Mangiola S, Kerger M, Furrer MA, Crowe H, Costello AJ, McBride DJ, Ross MT, Pope B, Hovens CM, Corcoran NM. Lau E, et al. Among authors: pope b. Genome Med. 2020 Aug 17;12(1):72. doi: 10.1186/s13073-020-00770-1. Genome Med. 2020. PMID: 32807235 Free PMC article.
MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer.
McCoy P, Mangiola S, Macintyre G, Hutchinson R, Tran B, Pope B, Georgeson P, Hong MKH, Kurganovs N, Lunke S, Clarkson MJ, Cmero M, Kerger M, Stuchbery R, Chow K, Haviv I, Ryan A, Costello AJ, Corcoran NM, Hovens CM. McCoy P, et al. Among authors: pope b. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1167-1180. doi: 10.1038/s41391-021-00379-4. Epub 2021 Jun 9. Prostate Cancer Prostatic Dis. 2021. PMID: 34108644
Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.
Burns D, Anokian E, Saunders EJ, Bristow RG, Fraser M, Reimand J, Schlomm T, Sauter G, Brors B, Korbel J, Weischenfeldt J, Waszak SM, Corcoran NM, Jung CH, Pope BJ, Hovens CM, Cancel-Tassin G, Cussenot O, Loda M, Sander C, Hayes VM, Dalsgaard Sorensen K, Lu YJ, Hamdy FC, Foster CS, Gnanapragasam V, Butler A, Lynch AG, Massie CE; CR-UK/Prostate Cancer UK, ICGC, The PPCG; Woodcock DJ, Cooper CS, Wedge DC, Brewer DS, Kote-Jarai Z, Eeles RA. Burns D, et al. Among authors: pope bj. Eur Urol. 2022 Aug;82(2):201-211. doi: 10.1016/j.eururo.2022.05.007. Epub 2022 May 31. Eur Urol. 2022. PMID: 35659150 Free article.
Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy.
Liow E, Howard N, Jung CH, Pope B, Campbell BK, Nguyen A, Kerger M, Ruddle JB, Anton A, Thomas B, Chu K, Dundee P, Peters JS, Costello AJ, Ryan AS, Hovens CM, Tran B, Corcoran NM. Liow E, et al. Among authors: pope b. Clin Genitourin Cancer. 2022 Oct;20(5):452-458. doi: 10.1016/j.clgc.2022.05.007. Epub 2022 May 18. Clin Genitourin Cancer. 2022. PMID: 35688680 Clinical Trial.
600 results